Processa Pharmaceuticals (PCSA) executive compensation, 2026 proxy

George Ng, Chief Executive Officer, was paid $673,303 in 2025, up 29% from $521,033 the year before.

Filed
October 22, 2026
Annual meeting
November 30, 2026
Pay year
2025
Named executives
3
CEO total pay
$673,303+29% vs prior year
CEO pay in equity
30%$199,373 in awards
CEO target bonus
50%of base compensation
CFO target bonus
40%of base compensation
NEO options granted
55,200 shares2025 grant
NEO RSUs granted
18,400 shares2025 grant

How Ng was paid

$673,303 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary59%Bonus7%Stock awards8%Option awards22%All other compensation4%

Named executive officers

ExecutiveTotal
George NgChief Executive Officer$673,303
Russell SkibstedChief Financial Officer$566,760
Sian BigoraFormer Chief Development and Regulatory Officer$495,097

What changed and why

  • $673K$673,303: CEO total compensation in 2025, compared with $521,033 in 2024.
  • $50,000$50,000 and $55,000: bonuses for Ng and Skibsted, respectively, for business development and financing deals.
  • $40,000$40,000: Bigora’s bonus recognized her past service and ongoing commitment.
  • 55,200 options and 18,400 RSUs were granted to NEOs in 2025, vesting over three years subject to continued service.
  • 50%Ng and Skibsted were eligible for executive bonus pools targeting 50% and 40% of base compensation, respectively.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.